Journal
PHYTOTHERAPY RESEARCH
Volume 37, Issue 4, Pages 1330-1345Publisher
WILEY
DOI: 10.1002/ptr.7689
Keywords
4-geranyloxy-2; 6-dihydroxybenzophenonel; Caco-2 cells; cAMP/PKA/CREB; CREB; NF-kappa B; ulcerative colitis
Categories
Ask authors/readers for more resources
This study found that 4-GDB can alleviate colonic injury, reduce inflammation, and improve colonic barrier function by regulating cAMP/PKA/CREB and NF-kappa B pathways. This suggests that 4-GDB may be a potential agent for treating ulcerative colitis.
Hypericum sampsonii Hance has traditionally been used to treat enteritis and diarrhea. As one of the main benzophenones isolated from H. sampsonii, 4-geranyloxy-2,6-dihydroxybenzophenonel (4-GDB) has been shown to possess anti-inflammatory effects. However, the therapeutic effect and potential mechanisms of 4-GDB in ulcerative colitis (UC) remain unclear. This study aimed to evaluate the role of 4-GDB in UC using a dextran sulfate sodium-induced colitis mouse model. Intragastric administration of 4-GDB (20 mg/kg/day) for 8 days significantly attenuated colonic injury, reduced the expression of inflammatory mediators, and improved colonic barrier function in mice with colitis. Furthermore, in vivo and in vitro experiments indicated that 4-GDB could activate cAMP/PKA/CREB and inhibit the NF-kappa B pathway. Collectively, 4-GDB may be a potential agent for treating UC by regulating the cAMP/PKA/CREB and NF-kappa B pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available